Michael Makris Profile picture
Dec 11 3 tweets 2 min read
Catherine Broome presented at #ASH22 results from a phase 3 RCT in ITP. Efgartigimod blocks the FcRn receptor and prevents Ig recirculation. It is given iv every 1-2 weeks. Efficacious in some patients. #ITP 1/3
It will be interesting to see how it compares to Rituxiamb and whether the hypoglobulinemia is associated with increased infections. Its role in the treatment of ITP (in comparison to other treatments) remains to be demonstrated. #ASH22 2/3
Efgartiginod is interesting since blockade of the FcRn receptor can be useful in other autoimmune and alloimmune disorders. I can see a lot more trials in other conditions using this molecule. #ASH22 3/3

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Michael Makris

Michael Makris Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ProfMakris

Aug 24
According to the article in @Nature on microclots and #longcovid the replication of the data is coming from a neuroscience group in Sheffield. I note this is unpublished work. This is an internationally important subject and I hope the authors submit a pre-print asap. 1/4 Image
We need to see how reproducible the data are. The facts that the number of subjects studied are so small and also that they are finding the microclots in people who have not had #COVID19 are of significant concern. 2/4
I would like to see the correlation between the results of these microclot assays with the more traditional and well established assays of coagulation activation such as D-Dimer and Prothrombin fragment 1+2. 3/4
Read 4 tweets
Jan 9
I joined the Biomarin conference this evening. Not much more info than the press release but here are a few snippets that I learned. 1/7
Biomarin phase 3 steroid use. Number of patients who needed steroids not mentioned. No mention of steroid adverse events. They said they just completed recruitment of a study that uses prophylactic steroids. 2/7
I believe that in #hemophilia gene therapy studies the adverse events due to steroids should be mentioned. These are high dose steroids for several weeks and adverse events are common. 3/7
Read 7 tweets
Jan 9
Biomarin has just announced their year 2 phase 3 (134 patients) ValRox gene therapy in #hemophilia results. Yes on a Sunday evening! Stable and durable bleed control but the FVIII levels are falling significantly. tinyurl.com/2p92ksj8 1/4
Key questions: How many patients needed steroids, what was the variability in levels (and how many had levels <10% and <5%), how long is the response predicted to last? #hemophilia #genetherapy #ValRox 2/4
Considering the mean FVIII levels, it is not surprising that stable and durable annual bleed control was observed. I would expect not many patients in the <10% group. Loss of ABR control would only be expected when the levels fall below 10%. #hemophilia #genetherapy 3/4
Read 4 tweets
Jun 3, 2021
What is the incidence of VITT after 2nd AZ vaccination? The MHRA are saying 1.3 per 1 million. I say it may be a lot less and could be zero. #VITT #COVIT19 1/7
We do not know much about the 2nd dose VITT cases that the MHRA claims to have had reported to them. They are all >50 but we do not know anything else. Why do they not publish type of thrombosis, age, sex, co-morbidities, anti-PF4? 2/7
It is accepted that the MHRA have had 18 reports of thrombosis with thrombocytopenia after 2nd dose AZ vaccine. But are they VITT? Do they definitely not have cancer or sepsis? Do they fulfil the attached typical VITT definition? 3/7 Image
Read 7 tweets
May 29, 2021
Health care workers and carers >18 years in the UK could get any vaccine relatively early on. Because of the Pfizer storage requirements, it was used largely in hospital vaccination sites. So in UK, hospital staff largely got Pfizer in contrast to Norway/Germany who got AZ. 1/4
In the UK this was a logistics issue since prior to March we knew nothing about VITT. Many European countries felt the efficacy data for the AZ vaccine were not strong for >65, so gave Pfizer to >65 and AZ to <65. 2/4
In Norway and Germany where the decision was to use AZ for <65 years, they also decided to give it to health care staff first. Since health care staff are more likely to be female, there was a large female excess in the persons who developed VITT. 3/4
Read 4 tweets
May 22, 2021
What is the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) after a 2nd AZ vaccine dose? This is the commonest question I get at present on twitter, email and in clinic. 1/6
The information released by the MHRA (the UK regulator) two days ago on their website stated that they have had 15 cases of 2nd dose VITT after 9 million 2nd doses of the AZ vacc administered (ie 1 VITT case every 600,000 2nd doses of the AZ vaccine). tinyurl.com/s53nf2w 2/6
If the rare of VITT in the UK after 2nd doses of the vaccine was the same as after the the 1st dose, we should have had (309-15)x9/23.9= 110.7 cases. According to the MHRA we have had 15 but expected 110. 3/6
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(